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Abstract
Background: Amyotrophic lateral sclerosis (ALS) is a fatal disorder caused by the progressive
degeneration of motoneurons in brain and spinal cord. Despite identification of disease-linked
mutations, the diversity of processes involved and the ambiguity of their relative importance in ALS
pathogenesis still represent a major impediment to disease models as a basis for effective therapies.
Moreover, the human motor cortex, although critical to ALS pathology and physiologically altered
in most forms of the disease, has not been screened systematically for therapeutic targets.
Results: By whole-genome expression profiling and stringent significance tests we identify genes
and gene groups de-regulated in the motor cortex of patients with sporadic ALS, and interpret the
role of individual candidate genes in a framework of differentially expressed pathways. Our findings
emphasize the importance of defense responses and cytoskeletal, mitochondrial and proteasomal
dysfunction, reflect reduced neuronal maintenance and vesicle trafficking, and implicate impaired
ion homeostasis and glycolysis in ALS pathogenesis. Additionally, we compared our dataset with
publicly available data for the SALS spinal cord, and show a high correlation of changes linked to
the diseased state in the SALS motor cortex. In an analogous comparison with data for the
Alzheimer's disease hippocampus we demonstrate a low correlation of global changes and a
moderate correlation for changes specifically linked to the SALS diseased state.
Conclusion: Gene and sample numbers investigated allow pathway- and gene-based analyses by
established error-correction methods, drawing a molecular portrait of the ALS motor cortex that
faithfully represents many known disease features and uncovers several novel aspects of ALS
pathology. Contrary to expectations for a tissue under oxidative stress, nuclear-encoded
mitochondrial genes are uniformly down-regulated. Moreover, the down-regulation of
mitochondrial and glycolytic genes implies a combined reduction of mitochondrial and cytoplasmic
energy supply, with a possible role in the death of ALS motoneurons. Identifying candidate genes
exclusively expressed in non-neuronal cells, we also highlight the importance of these cells in
disease development in the motor cortex. Notably, some pathways and candidate genes identified
by this study are direct or indirect targets of medication already applied to unrelated illnesses and
point the way towards the rapid development of effective symptomatic ALS therapies.
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Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscu-
lar disorder affecting 1–2 in 100,000 persons. It is caused
by the degeneration of motoneurons in brain and spinal
cord, leading to muscle atrophy, progressive paralysis, and
death, commonly by respiratory failure. Most cases of ALS
are sporadic (SALS) and about 10% familial (FALS), with
mutant forms of copper-zinc superoxide dismutase
(SOD1) causing 20% of FALS cases. Findings in ALS
patients and model systems have implicated numerous
genes in ALS pathogenesis, and have identified diverse
processes, such as oxidative stress, excitotoxicity, mito-
chondrial dysfunction, protein aggregation, cytoskeletal
abnormalities, impaired axonal transport, inflammation,
and apoptosis, as contributing factors [1]. As a mainly
sporadic disease affecting multiple cellular processes, ALS
therefore suggests itself for comprehensive expression
profiling and gene- and pathway-based analyses. The few
existing genomics studies of ALS [2-4], however, have had
limited genome coverage and have been restricted to
gene-based analyses.
Adding a further layer of complexity, ALS is a highly het-
erogenous disease, with clinical indicators helping to
define ALS subtypes. One such indicator is a differential
depletion of motoneurons in motor cortex and spinal
cord [5-7], giving significance to the characterization of
both tissues. The motor cortex contains upper motoneu-
rons (UMNs), which extend axons traversing the corticos-
pinal tract to signal to the spinal cord, where lower
motoneurons (LMNs) relay their signal. The corticospinal
tract volume is reduced [8] and UMNs are depleted [9,10]
in ALS patients, and UMNs are required for LMN function
and muscle control [11]. Most importantly, patients with
sporadic, non-SOD1-associated forms of ALS show altera-
tions in the motor cortex, such as increased excitability
and reduced inhibitory activity, which are not readily
detectable in SOD1-linked FALS patients, thus stressing
the particular importance of investigating the motor cor-
tex in SALS subjects [12-14]. Possibly owing to earlier clin-
ical manifestations of defects in LMNs and their easier
accessibility to experimenters, however, most investiga-
tions of ALS, including previous genomics studies [2-4],
focus on the spinal cord and LMNs, leaving ALS-related
responses and defects of cellular maintenance in the
motor cortex under-investigated.
Here we address the importance of UMN abnormalities in
SALS pathology and exploit the power of pathway-based
significance tests by whole-genome expression profiling
of the motor cortex of SALS patients. We identify differen-
tially expressed genes and pathways, interpret the role of
candidate genes in ALS pathology using these pathways as
a functional outline, and evaluate the implications of our
findings for ALS research and the development of ALS
therapies.
Results
Expression profiling of the motor cortex of SALS patients
We investigated the motor cortex of eleven SALS and nine
control subjects (see Table 1) with whole-genome oligo-
nucleotide microarrays and following microscopic assess-
ment of tissue architecture (see Figure 1 for Nissl staining
of six representative samples). Out of over 41,000 genes
and expressed sequence tags tested, 19,431 genes passed
our quality control criteria (see the Methods section), con-
stituting our complete data set for subsequent analyses.
Median and average fold-changes of our complete data set
were 1.01 (Diseased vs. Control), establishing that no sys-
tematic bias for up- or down-regulation was introduced
into subsequent statistical analyses.
To exploit the comprehensiveness of our data, we com-
bined two complementary, stringent approaches, investi-
gating changes in the SALS motor cortex for functional
gene groups and on the level of individual genes.
Pathway-based analysis
We first performed a pathway-based analysis of the com-
plete data set by testing changes of gene expression in the
context of 5137 gene groups of the gene ontology (GO)
hierarchy, using the GenMAPP 2.0 software. Analyses on
the level of functional gene groups lead to a biologically
transparent picture of expression, accessible to interpreta-
tion. What is more, by combining measurements for func-
tionally related genes this approach increases the
sensitivity of detecting significant changes when differen-
tial gene expression is diluted in a mixed cell population
(leading to comparably low fold changes) and with small
to moderate sample numbers (possibly leading to a high
variance for inconsistently de-regulated genes). In such
instances individual genes will not pass statistical criteria
for differential gene expression, while moderate deregula-
tion of multiple genes constituting a functional group
might test highly significant. Indeed, the statistical signif-
icances we derived from GenMAPP 2.0, using the average
fold-change per gene as a basis for statistical tests, is inde-
pendent of the number of samples and highly dependent
on the number of genes represented by our data, while the
quality filtering and the comparably large number of sam-
ples used in this study avoid the detection of spurious
results and promote a correspondence between statistical
and biological significance. In other words, 5137 GO cat-
egories were probed with 19,431 quality filtered genes,
and 20 samples were used to derive representative average
fold-changes to do so. GenMAPP detected 5033 GO cate-
gories as unchanged, while 104 partially redundant cate-
gories exhibited significantly changed expression in ALS
subjects (corrected P < 0.05). Significant GO categoriesPage 2 of 26
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a comprehensive ALS disease model, five of them down-
regulated and one up-regulated (Figure 2; see Table 2 for
the full list of significantly changed GO categories).
Identification of candidate genes
We then analyzed the complete data set for individual
genes showing differential gene expression, finding that
57 of the 19,431 quality-filtered genes (0.3%) fulfilled
our stringent criteria (including Benjamini and Hochberg
multiple testing correction, for details see the Methods sec-
tion), with 40 genes showing down-regulation and 17 up-
regulation in SALS subjects (Figure 3). In contrast to
results for large gene groups, differential expression of
individual mRNAs is readily verifiable by alternative tech-
niques, such as quantitative RT-PCR (qRT-PCR) and in-
situ hybridization.
Confirmation by quantitative RT-PCR
The 60-mer oligonucleotide format of microarrays used in
this study may provide tolerance for sequence mis-
matches. To investigate probe-target specificity, the
sequences of oligonucleotide probes corresponding to dif-
ferentially expressed genes were compared to GenBank
sequences by BLASTN queries. The only probes showing
up to ten mismatches with more than one gene were seven
metallothioneins (MT1B, MT1E, MT1G, MT1L, MT1M,
MT1X, MT2A). To discriminate among these homologous
genes and analyze their differential expression we used
qRT-PCR. PVALB, down-regulated in the ALS motor cor-
tex, was also included in our qRT-PCR analysis as a posi-
tive control for the correspondence of microarray and
qRT-PCR data. In contrast to the metallothionein probes
the PVALB probe, representative of probes for the remain-
ing candidates, detects transcripts for a single gene, only.
PVALB and six of the metallothioneins were specifically
quantifiable by qRT-PCR (Figure 4). Microarray and qRT-
PCR results were concordant (correlation coefficient r =
0.91, comparing individual test and control averages for
the seven genes tested), confirming up-regulation of six
metallothioneins and down-regulation of PVALB in the
SALS motor cortex. MT1B, whose microarray probe shares
Table 1: Characteristics of subjects
Sample ID Sample 
Type
Order Code Chief Disease Cause of Death Age
[years/days]
Gender Race PMI [h]
Control 1 tissue BTB3428 A drowning drowning 56/275 Female Caucasian 17
Control 2 tissue BTB3576A hypertension ruptured abdominal 
aortic aneurism
59/260 Male Caucasian 15
Control 3 tissue BTB3577A n/a n/a 59/118 Male Caucasian 21




60/- Male Hispanic White 17
Control 5 tissue HCtANA n/a n/a 72/- Male Caucasian 11
Control 6 tissue HCtAVA n/a n/a 84/- Female Caucasian 2.75
Control 7 tissue HCtEUA coronary artery 
disease
n/a 79/- Female Caucasian 7.5
Control 8 tissue HCtFMA n/a n/a 70/- Female Caucasian 8.5
Control 9 RNA 6782B thrombosis and 
coronary 
atherosclerosis
heart attack 68/- Male Caucasian n/a
Diseased 1 tissue BTB3226 A ALS respiratory failure 
with probable early 
pneumonia
71/18 Male Caucasian 19
Diseased 2 tissue BTB3235 A ALS respiratory failure 73/106 Male Caucasian 5.5
Diseased 3 tissue BTB3461 A ALS ALS 77/53 Male Caucasian 7.5
Diseased 4 tissue BTB3580A ALS respiratory failure 58/83 Male Caucasian 22
Diseased 5 tissue BTB3583A ALS respiratory distress 52/54 Female Hispanic White 20.5
Diseased 6 tissue BTB3590A ALS pneumonia 75/- Male Caucasian 24
Diseased 7 tissue BTB3603A ALS N/A 67/325 Female Caucasian 17
Diseased 8 tissue BTB3611A ALS N/A 69/90 Female Caucasian 13
Diseased 9 tissue BTB3689A ALS N/A 61/141 Female Caucasian 22
Diseased 10 tissue BTB3713A ALS ALS 66/252 Male Caucasian 13
Diseased 11 RNA 6166B ALS respiratory failure 70/- Male Caucasian n/a
20 motor-cortex samples of eleven ALS patients and nine controls were analyzed on individual Whole Human Genome Arrays for genome-wide 
expression profiling. Age, gender, race, and post-mortem interval (mean controls 12.47 ± 6.06 h and mean patients 16.35 ± 6.37 h, P = 0.21) are 
shown for all tissue samples. A – Miami Brain and Tissue Bank for Developmental Disorders; B – Ambion, Inc.; n/a – not availablePage 3 of 26
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specifically by three independent primer pairs, and was
excluded from subsequent analyses.
Confirmation by in-situ hybrization
To verify the microarray results in a direct fashion (i.e.
without intervening reverse-transcription and amplifica-
tion steps), we then performed double-blind in-situ
hybridization for four candidate genes in human motor
cortex sections from five control and five SALS subjects.
Median fluorescence levels of entire tissue sections for dis-
eased and control subjects were measured for four candi-
date genes (ANXA2, ATP1A3, NRGN, and PVALB, see
Figure 5), showing a strong correlation with the micro-
array data (correlation coefficient r = 0.97, comparing
individual test and control averages for the four genes
tested).
Confirmation at the protein level
We then proceeded to validate our findings for mRNAs at
the level of proteins, which for the overwhelming major-
ity of RNAs investigated in this study represent the biolog-
Architecture of the motor cortex in SALS and control samplesFigur  1
Architecture of the motor cortex in SALS and control samples. Nissl staining of representative SALS samples (D2, 
D4, D5) and controls (H1, H3, H4) shows the intact architecture of the motor cortex in samples chosen for expression analy-
sis. All samples are shown at identical magnification. Cell layers are color-coded as indicated for sample D2. ML – molecular 
layer; EGL – external granular layer; EPL – external pyramidal layer; IGL – internal granular layer; IPL – internal pyramidal layer; 
MFL – multiform layer; WM – white matter. The scale bar indicates 500 μm.
D2 D4 D5 H1 H3 H4
     






MFLPage 4 of 26
(page number not for citation purposes)
BMC Genomics 2007, 8:26 http://www.biomedcentral.com/1471-2164/8/26ically active equivalent. While individual genes may show
discrepancies between mRNA and protein levels, owing to
translational and post-translational control, an on average
fair correlation between protein and mRNA levels can be
expected in mammalian systems [15]. Protein extracts of
three healthy and six diseased samples, equalized for total
protein content, were analyzed by immunoblotting (see
Figure 6A and 6B). Quantification of protein levels
revealed an up-regulation for ANXA2 (18.56-fold) and
AQP1 (4.94-fold), and a down-regulation of NRGN
(0.38-fold) in diseased samples. These findings were in
line with and exceeded the fold-changes of 2.06, 2.52, and
Gene Ontology nodes differentially expressed in motor cortex of SALS subjectsFigure 2
Gene Ontology nodes differentially expressed in motor cortex of SALS subjects. Significant Gene Ontology (GO) 
nodes were combined to groups likely representing major processes in the context of ALS pathology, specifically energy metab-
olism, ion homeostasis and solute transport, defense signaling, protein modification and turnover, cytoskeleton, and glycolysis, and are 
arranged indicating the predominant intracellular localization of the gene products they comprise. The basic categories Biolog-
ical Process, Cellular Component, and Molecular Function are color-coded. Connecting arrows indicate the order of nodes in 
the GO hierarchy. For each major process only the highest node(s) of significance () and the most significant node (!) are 
shown per basic category. Up- ( ) and down-regulation ( ), the absolute number and percentage of genes meeting the crite-
rion, z score, and corrected P value are indicated for each node. Redundant nodes are left out within the same category, or 
combined if in different categories.
Å ÆPage 5 of 26
(page number not for citation purposes)
BMC Genomics 2007, 8:26 http://www.biomedcentral.com/1471-2164/8/26Table 2: Differentially regulated GO categories
Up-regulated GO categories






z Score corrected P
6955 immune response BP 106 346 30.64 7.84 0
9607 response to biotic stimulus BP 130 456 28.51 7.77 0
6952 defense response BP 113 381 29.66 7.71 0
50874 organismal physiological process BP 208 859 24.21 7.30 0
50896 response to stimulus BP 215 941 22.85 6.45 0
43207 response to external biotic stimulus BP 71 235 30.21 6.24 0
9613 response to pest\, pathogen or parasite BP 69 228 30.26 6.16 0
9605 response to external stimulus BP 134 563 23.80 5.51 0.01
4871 signal transducer activity MF 251 1199 20.93 5.44 0.011
9596 detection of pest\, pathogen or parasite BP 5 5 100.00 5.19 0.047
2453 probes met the [fold-change]>=1.2 criterion.
1782 probes meeting the filter linked to an Ensembl ID.
1323 genes meeting the criterion linked to a GO term.
The z score is based on an N of 8457 and an R of 1323 distinct genes in the GO.
Down-regulated GO categories






z Score corrected P
15077 monovalent inorganic cation transporter activity MF 86 120 71.67 13.88 0
15078 hydrogen ion transporter activity MF 80 111 72.07 13.44 0
15399 primary active transporter activity MF 88 131 67.18 13.23 0
16655 oxidoreductase activity\, acting on NADH or NADPH\, 
quinone or similar compound as acceptor
MF 37 42 88.10 10.81 0
5739 mitochondrion CC 186 459 40.52 10.78 0
3954 NADH dehydrogenase activity MF 34 38 89.47 10.49 0
6119 oxidative phosphorylation BP 47 64 73.44 10.45 0
50136 NADH dehydrogenase (quinone) activity MF 33 37 89.19 10.30 0
8137 NADH dehydrogenase (ubiquinone) activity MF 33 37 89.19 10.30 0
16651 oxidoreductase activity\, acting on NADH or NADPH MF 43 57 75.44 10.23 0
15081 sodium ion transporter activity MF 34 40 85.00 10.06 0
19866 inner membrane CC 62 114 54.39 8.94 0
42775 ATP synthesis coupled electron transport (sensu 
Eukaryota)
BP 22 24 91.67 8.59 0
5737 cytoplasm CC 547 1987 27.53 8.58 0
6091 generation of precursor metabolites and energy BP 143 375 38.13 8.52 0
8324 cation transporter activity MF 127 324 39.20 8.38 0
42773 ATP synthesis coupled electron transport BP 22 25 88.00 8.32 0
5740 mitochondrial membrane CC 59 115 51.30 8.15 0
46873 metal ion transporter activity MF 42 70 60.00 8.15 0
15075 ion transporter activity MF 146 397 36.78 8.10 0
5386 carrier activity MF 109 271 40.22 8.06 0
6120 mitochondrial electron transport\, NADH to ubiquinone BP 19 21 90.48 7.90 0
5743 mitochondrial inner membrane CC 48 89 53.93 7.78 0
6096 glycolysis BP 22 30 73.33 7.13 0
6754 ATP biosynthesis BP 26 41 63.41 6.77 0
6753 nucleoside phosphate metabolism BP 26 41 63.41 6.77 0
9206 purine ribonucleoside triphosphate biosynthesis BP 30 51 58.82 6.74 0
9145 purine nucleoside triphosphate biosynthesis BP 30 51 58.82 6.74 0
9201 ribonucleoside triphosphate biosynthesis BP 30 51 58.82 6.74 0
6092 main pathways of carbohydrate metabolism BP 35 64 54.69 6.74 0
15992 proton transport BP 31 54 57.41 6.68 0
16818 hydrolase activity\, acting on acid anhydrides\, in 
phosphorus-containing anhydrides
MF 124 358 34.64 6.65 0
16817 hydrolase activity\, acting on acid anhydrides MF 124 358 34.64 6.65 0
9142 nucleoside triphosphate biosynthesis BP 30 52 57.69 6.60 0Page 6 of 26
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9199 ribonucleoside triphosphate metabolism BP 31 55 56.36 6.55 0
9144 purine nucleoside triphosphate metabolism BP 31 55 56.36 6.55 0
6818 hydrogen transport BP 31 55 56.36 6.55 0
9205 purine ribonucleoside triphosphate metabolism BP 31 55 56.36 6.55 0
46034 ATP metabolism BP 27 45 60.00 6.52 0
16462 pyrophosphatase activity MF 122 356 34.27 6.45 0
46961 hydrogen-transporting ATPase activity\, rotational 
mechanism
MF 23 36 63.89 6.41 0
16469 proton-transporting two-sector ATPase complex CC 23 36 63.89 6.41 0
9152 purine ribonucleotide biosynthesis BP 33 62 53.23 6.34 0
9141 nucleoside triphosphate metabolism BP 31 57 54.39 6.30 0
15985 energy coupled proton transport\, down electrochemical 
gradient
BP 23 37 62.16 6.24 0
6007 glucose catabolism BP 23 37 62.16 6.24 0
15986 ATP synthesis coupled proton transport BP 23 37 62.16 6.24 0
15980 energy derivation by oxidation of organic compounds BP 46 101 45.54 6.20 0
5489 electron transporter activity MF 67 168 39.88 6.20 0
45259 proton-transporting ATP synthase complex CC 10 10 100.00 6.19 0
45255 hydrogen-translocating F-type ATPase complex CC 10 10 100.00 6.19 0
5753 proton-transporting ATP synthase complex (sensu 
Eukaryota)
CC 10 10 100.00 6.19 0
46933 hydrogen-transporting ATP synthase activity\, rotational 
mechanism
MF 22 35 62.86 6.17 0
42625 ATPase activity\, coupled to transmembrane movement 
of ions
MF 32 61 52.46 6.14 0
19829 cation-transporting ATPase activity MF 23 38 60.53 6.07 0
17111 nucleoside-triphosphatase activity MF 114 338 33.73 6.03 0
9150 purine ribonucleotide metabolism BP 33 65 50.77 6.01 0
6164 purine nucleotide biosynthesis BP 33 65 50.77 6.01 0
45298 tubulin BP 15 20 75.00 6.00 0
46785 microtubule polymerization CC 15 20 75.00 6.00 0
9260 ribonucleotide biosynthesis BP 33 66 50.00 5.90 0
31109 microtubule polymerization or depolymerization BP 17 25 68.00 5.84 0
9259 ribonucleotide metabolism BP 34 70 48.57 5.78 0
46164 alcohol catabolism BP 23 40 57.50 5.76 0
46365 monosaccharide catabolism BP 23 40 57.50 5.76 0
19320 hexose catabolism BP 23 40 57.50 5.76 0
6752 group transfer coenzyme metabolism BP 27 51 52.94 5.70 0
6163 purine nucleotide metabolism BP 33 68 48.53 5.69 0
15002 heme-copper terminal oxidase activity MF 13 17 76.47 5.68 0
16676 oxidoreductase activity\, acting on heme group of 
donors\, oxygen as acceptor
MF 13 17 76.47 5.68 0
16675 oxidoreductase activity\, acting on heme group of donors MF 13 17 76.47 5.68 0
4129 cytochrome-c oxidase activity MF 13 17 76.47 5.68 0
6732 coenzyme metabolism BP 45 107 42.06 5.49 0
42626 ATPase activity\, coupled to transmembrane movement 
of substances
MF 36 79 45.57 5.48 0
16820 hydrolase activity\, acting on acid anhydrides\, catalyzing 
transmembrane movement of substances
MF 36 79 45.57 5.48 0
43234 protein complex CC 313 1175 26.64 5.41 0
51186 cofactor metabolism BP 50 125 40.00 5.36 0
6006 glucose metabolism BP 27 54 50.00 5.33 0
5215 transporter activity MF 240 871 27.55 5.27 0
45333 cellular respiration BP 17 28 60.71 5.23 0
51258 protein polymerization BP 18 31 58.06 5.14 0.002
226 microtubule cytoskeleton organization and biogenesis BP 25 50 50.00 5.13 0.004
31090 organelle membrane CC 89 270 32.96 5.05 0.004
7017 microtubule-based process BP 38 93 40.86 4.82 0.01
502 proteasome complex (sensu Eukaryota) CC 18 33 54.55 4.81 0.016
16052 carbohydrate catabolism BP 24 50 48.00 4.78 0.025
44275 cellular carbohydrate catabolism BP 24 50 48.00 4.78 0.025
9117 nucleotide metabolism BP 48 128 37.50 4.73 0.026
Table 2: Differentially regulated GO categories (Continued)Page 7 of 26
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3924 GTPase activity MF 44 116 37.93 4.61 0.043
16491 oxidoreductase activity MF 115 383 30.03 4.61 0.044
5829 cytosol CC 69 207 33.33 4.54 0.045
9165 nucleotide biosynthesis BP 38 97 39.18 4.52 0.045
3059 probes met the [fold-change]<=(1/1.2) criterion.
2522 probes meeting the filter linked to an Ensembl ID.
1751 genes meeting the criterion linked to a GO term.
The z score is based on an N of 8457 and an R of 1751 distinct genes in the GO.
Shown are all GO nodes differentially regulated between SALS motor-cortex-patient samples and controls for the comprehensive dataset. Of 
19,431 probes in the dataset, 8,457 were linked to a GO term. Nodes are sorted by up- or down-regulation (top and bottom sub-tables, 
respectively), then sorted by corrected P value (lowest first) and z value (highest first). CC – cellular component; MF – molecular function; BP – 
biological process
Table 2: Differentially regulated GO categories (Continued)0.49, respectively, detected by microarray-based analysis
for the corresponding mRNAs. Remarkably, AQP1 is gen-
erally assumed to be absent from the motor cortex, with a
predominant expression in the brain in the choroid
plexus [16] and in glial cells in the peripheral nervous sys-
tem [17]. We therefore also performed immunofluores-
cence analyses of motor-cortical sections to elaborate our
findings (Figure 6C), demonstrating the presence of AQP1
in non-neuronal cells in the motor cortex.
Comparison with SALS spinal-cord and AD hippocampus 
expression data
We then compared expression ratios diseased vs. control
for the SALS motor cortex to previously published data for
spinal cord grey matter [4]. A comparison of all 2266
genes reliably detected in both tissues showed a negligible
correlation (r = 0.04), while 23 of the motor-cortex candi-
date genes also present in the reduced data set showed a
high correlation (r = 0.85) between both tissues (see the
Methods section and Table 3).
To assess in how far responses detected in the motor cor-
tex of SALS patients might be shared with other neurode-
generative diseases, we then compared our data to
expression ratios diseased vs. healthy for previously pub-
lished data by Blalock et al. [18] for the hippocampus of
patients with severe Alzheimer's disease (AD). A compar-
ison of all 6375 genes reliably detected in both tissues
showed a low correlation (r = 0.38), while 38 of the
motor-cortex candidate genes also present in the reduced
data set showed a moderate correlation (r = 0.70) between
both tissues (see the Methods section and Table 4).
Despite the distinctive clinical manifestations of AD and
its action on different areas of the central nervous system,
therefore, global responses in the AD hippocampus corre-
spond more closely to those in the SALS motor cortex
than do those in the SALS spinal cord. This observation
might reflect similar general changes in both brain tissues
under long-term stress and after prolonged disease pathol-
ogy, and ties in with the implication of processes such as
oxidative stress, reduced energy metabolism, intracellular
protein aggregation, and inflammation in both, AD and
ALS pathogenesis. Importantly and similar to our findings
for the SALS motor cortex, Blalock et al. [18] detected ATP
biosynthesis and glycolysis by pathway-based analysis as sig-
nificantly reduced in AD, and found deregulation in line
with ours for defense response and microtubule-based process,
albeit below the significance threshold. Changes signifi-
cantly linked to the diseased state in our study, however,
are highly correlated between SALS motor cortex and spi-
nal cord, and less similar between SALS motor cortex and
AD hippocampus. In particular, ATP1A3, EGR1, and
CHGB experience opposing deregulation in the SALS
motor cortex compared to the AD hippocampus, with
ANXA2, ATP6V1A, EIF4A2, NSF, and all the metal-
lothioneins detected in the hippocampus (MT1E, MT1G,
MT1X, MT2A) also showing markedly different regulation
between both tissues.
Discussion
A framework for the understanding of ALS pathogenesis
A combination of candidate genes and pathway-based
analysis provided a comprehensive view, at the level of
mRNA, of the processes involved in ALS pathogenesis,
suggesting an interpretation of changes in gene expression
within a framework of deregulated pathways (Figure 7). It
should be pointed out that, inherent to the analysis of
end-stage diseased tissue, microarray analysis cannot dis-
tinguish between bona-fide up- and down-regulation of a
gene and the selective survival and death, respectively, of
cells highly expressing it. This ambiguity generally does
not alter the interpretation of the role a given candidate
gene with an established function might play in disease
pathology. Moreover, selective cell death or survival
appear unlikely explanations for the identification of can-
didate genes with two-fold changes of expression. How-
ever, this limitation needs to be borne in mind and will
not be re-itterated in the course of the discussion. Nearly
all candidate genes identified by this study may be actorsPage 8 of 26
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Genes differentially expressed in motor cortex of SALS subjectsFigure 3
Genes differentially expressed in motor cortex of SALS subjects. 57 of 19,431 quality-filtered genes (0.3%), repre-
sented by 61 probes, are differentially expressed (corrected P < 0.05), with each row in the matrix representing a single probe 
and each column a subject. Normalized expression levels are represented by the color of the corresponding cell, relative to 
the median abundance of each gene for each subject (see scale). Genes are named using their UniGene symbol and arranged in 
a hierarchical cluster (standard correlation) based on their expression patterns, combined with a dendrogram whose branch 
lengths reflect the relatedness of expression patterns. For each gene the fold-change (diseased vs. control) and corrected P 
value are given.
control disease fold- p- gene gene
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 10 11 change value symbol name
0.41 0.0187 MDH1 Malate dehydrogenase 1, NAD (soluble)
0.48 0.0278 UCHL1 Ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase)
0.45 0.0187 NSF N-ethylmaleimide-sensitive factor
0.45 0.0151 MLLT11 Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 11
0.40 0.0151 BEX1 Brain expressed, X-linked 1
0.35 0.0157 VSNL1 Visinin-like 1
0.50 0.0187 SYT13 Synaptotagmin XIII
0.32 0.0189 NEFL Neurofilament, light polypeptide 68kDa
0.39 0.0151 CHGB Chromogranin B (secretogranin 1)
0.45 0.0157 KCNC2 Potassium voltage-gated channel, Shaw-related subfamily, member 2
0.39 0.0105 PCSK1 Proprotein convertase subtilisin/kexin type 1
0.43 0.0109 OLFM1 Olfactomedin 1
0.48 0.0205 YWHAH Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide
0.48 0.0251 CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast)
0.47 0.0151 NAP1L5 Nucleosome assembly protein 1-like 5
0.31 0.0151 SNAP25 Synaptosomal-associated protein, 25kDa
0.46 0.0204 PNMA2 Paraneoplastic antigen MA2
0.34 0.0192 ENC1 Ectodermal-neural cortex (with BTB-like domain)
0.49 0.0105 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide
0.46 0.0189 RTN1 Reticulon 1
0.50 0.0151 NPTN Neuroplastin
0.50 0.0151 SLC12A5 Solute carrier family 12, (potassium-chloride transporter) member 5
0.47 0.0105 GABRA1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1
0.49 0.0105 ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A
0.49 0.0204 NEFL Neurofilament, light polypeptide 68kDa
0.45 0.0301 EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2
0.48 0.0257 GNAS GNAS complex locus
0.49 0.0222 TUBB2A Tubulin, beta 2A
0.42 0.0189 CHN1 Chimerin (chimaerin) 1
0.48 0.0189 ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac muscle
0.43 0.0187 RTN4 Reticulon 4
0.48 0.0205 SCG5 secretogranin V (7B2 protein)
0.49 0.0105 CYCS Cytochrome c, somatic
0.48 0.0105 NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa
0.49 0.0229 NRGN Neurogranin (protein kinase C substrate, RC3)
0.38 0.0187 NEF3 neurofilament 3 (150kDa medium)
0.47 0.0187 OLFM1 Olfactomedin 1
0.49 0.0151 PCP4 Purkinje cell protein 4
0.40 0.0105 PVALB Parvalbumin
0.46 0.0105 EGR1 Early growth response 1
0.37 0.0204 NEFH Neurofilament, heavy polypeptide 200kDa
0.49 0.0189 DSCR1L1 Down syndrome critical region gene 1-like 1
2.43 0.0105 MT2A Metallothionein 2A
2.50 0.0151 MT2A Metallothionein 2A
2.29 0.02 MT1E Metallothionein 1E (functional)
2.19 0.023 MT1G Metallothionein 1G
2.27 0.0187 MT2A Metallothionein 2A
2.00 0.0263 MT1B Metallothionein 1B (functional)
2.13 0.0251 MT1L Metallothionein 1L
2.02 0.0306 MT1X Metallothionein 1X
2.14 0.0256 MT1M Metallothionein 1M
2.52 0.0151 CEBPD CCAAT/enhancer binding protein (C/EBP), delta
4.12 0.0105 S100A8 S100 calcium binding protein A8 (calgranulin A)
2.05 0.0105 TUBB6 Tubulin, beta 6
2.06 0.0105 ANXA2 Annexin A2
2.05 0.022 EDN1 Endothelin 1
2.28 0.0316 ANGPTL4 Angiopoietin-like 4
2.52 0.0364 AQP1 Aquaporin 1 (Colton blood group)
2.15 0.0151 SLC14A1 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group)
2.38 0.0256 SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
2.00 0.0269 FCGBP Fc fragment of IgG binding protein
fold change
5.00.2
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tions, and some of them stand out as potentially critical to
de-regulated processes and to ALS therapy.
Mitochondrial energy metabolism
Mitochondrial energy metabolism is a process down-regu-
lated at the mRNA level and represented by all three major
GO categories and by genes contributing to the tricarbox-
ylic acid (TCA) cycle (MDH1) and involved in oxidative
phosphorylation (CYCS, NDUFA4 and ATP5A1). The TCA
accepts glycolysis-derived pyruvate as a key entry compo-
nent. An alternative route for the supply of the TCA with
pyruvate is its import downstream of the down-regulated
MDH1, the cytosolic malate dehydrogenase [19]. Down-
stream of the TCA, oxidative phosphorylation occurs, for
which we detected a specific down-regulation of genes
encoding NDUFA4, a component of complex I of the elec-
tron transport chain in the inner mitochondrial mem-
brane, CYCS, facilitating electron transport from complex
III to complex IV in the intramembrane space, and
ATP5A1, a component of the ATP synthase in the inner
mitochondrial membrane. Importantly, the down-regu-
lated CYCS is not only a component of mitochondrial oxi-
dative phosphorylation, but also represents a cytoplasmic
signal for neuronal apoptosis as a result of impaired mito-
chondrial integrity. Opening of the mitochondrial transi-
tion pore normally serves the ion exchange between
matrix and cytosol, but is thought to be exaggerated upon
excitotoxic levels of Ca2+, leading to release of CYCS from
the mitochondrion [20]. CYCS release, its activation of
cellular caspases, and subsequent apoptosis have been
proposed as a contributing factor to neuronal cell death in
ALS [1]. A lowered expression of CYCS, however, would
conceivably decrease the sensitivity to stress-induced
apoptosis [21]. More significantly, our observations
expand a role for mitochondrial dysfunction in the death
of ALS motoneurons, which is otherwise mainly under-
stood as a consequence of mitochondrial recruitment of
mutant SOD1 in FALS [1], and which was even ruled out
for SALS by one study [22]. Importantly, the significant
down-regulation of GO nodes relating to mitochondria
can not be the mere consequence of mitochondrial dys-
function or reduced numbers of mitochondria, as the GO
hierarchy does not represent mitochondrion-encoded
transcripts. Moreover, nuclear-encoded transcripts encod-
ing mitochondrial proteins are universally induced during
conditions of oxidative stress and mitochondrial damage
[23], contrary to our observations for motor-cortical cells
of SALS patients.
Changes of ANXA2, ATP1A3, NRGN, and PVALB mRNAs in motor cortex of S LS subjectsFigur  5
Changes of ANXA2, ATP1A3, NRGN, and PVALB 
mRNAs in motor cortex of SALS subjects. In-situ 
hybridization analysis of ANXA2, ATP1A3, NRGN, and 
PVALB mRNAs was performed in duplicate tissue sections of 
motor cortex from five control and five SALS subjects. Opti-
cal density values were normalized against those obtained in 
control subjects and subjected to two-tailed Student's t-test 
(with the P values 3.44e-6 (ANXA2), 7.91e-3 (ATP1A3), 
2.29e-5 (NRGN) and 2.88e-6 (PVALB), respectively, diseased 
vs. control). The bar graph shows mean results and the 
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Comparison of microarray and qRT-PCR results for selected candid te genesFigure 4
Comparison of microarray and qRT-PCR results for 
selected candidate genes. The bar graph shows mean 
results of expression levels in SALS vs. control subject. Fold-
changes are shown diseased vs. control, and differed by less 
than 1.2-fold between qRT-PCR and microarray, except for 
MT1E and MT2A. Error bars for qRT-PCR data indicate the 
range for duplicate experiments. The P values for qRT-PCR 
and microarray (most significant probe) data were 0.342 and 
0.020 (MT1E), 0.063 and 0.023 (MT1G), 0.037 and 0.025 
(MT1L), 0.119 and 0.026 (MT1M), 0.074 and 0.031 (MT1X), 
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Immunodetection of selected candidate genesFigure 6
Immunodetection of selected candidate genes. (A) Immunoblots for ANXA2, AQP1, NRGN, and CANX was per-
formed for three control and six diseased subjects. The size of quantified bands is indicated in kDa. The glycosylated form of 
AQP1 (*), undetectable in the healthy samples analyzed, was not included in the analysis. CANX served as a reference gene for 
sample normalization. (B) Bar graph comparing fold-changes of mean expression levels diseased vs. control as detected by 
immunoblot and microarray. Normalized intensity values are shown diseased vs. control and were analyzed by a two-tailed 
Student's t-test. P values for immunoblot and microarray (most significant probe) data were 0.025 and 0.011 (ANXA2), 0.055 
and 0.036 (AQP1), and 0.047 and 0.023 (NRGN), respectively). (C) Immunofluorescence detection of AQP1 expression in 
non-neuronal cells in the diseased (D) and the healthy (H) motor cortex. NF – neurofilaments (red); AQP1 – aquaporin 1 
(green); DNA – Hoechst33342 counterstain (blue). The scale bar indicates 100 μm.
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Glycolysis was detected as significantly down-regulated in
the SALS motor cortex by pathway-based analysis of our
microarray data. Glycolysis represents the cytoplasmic
alternative to mitochondrial ATP generation by the TCA
cycle and by oxidative phosphorylation, but is also a
major source of pyruvate supply to the TCA cycle. At the
level of individual genes, significant changes in gene
expression similarly indicate a reduction of glycolysis
(ANGPTL4) and glucose availability (CHGB, SCG5,
PCSK1). The up-regulation of ANGPTL4 reduces expres-
sion of genes involved in glycolysis and gluconeogenesis
[24]. The down-regulation of granins CHGB and SCG5,
both processed by the down-regulated prohormone con-
vertase PCSK1, increases insulin levels, hence reducing the
availability of glucose for glycolysis [25]. In the context of
ALS-related oxidative stress and neuronal modulation of
ion gradients, a reduction of glycolytic energy supply, in
combination with reduced mitochondrial energy supply,
would constitute a major cause for neuronal cell death.
Ion homeostasis and solute transport
Ion homeostasis and solute transport is detected as reduced at
the mRNA level by pathway-based analysis and covers
both cytoplasmic and mitochondrial events (see Table 2).
For instance, 71.7% of monovalent inorganic cation trans-
porter activity includes genes involved in proton transport
(hydrogen ion transporter activity, z = 13.444, P = 0), com-
monly associated with organelle membranes (e.g. of
mitochondria and lysosomes), and genes involved in the
transport of sodium ions (sodium ion transporter activity, z
= 10.059, P = 0) and metal ions in general (metal ion trans-
porter activity, z = 8.147, P = 0), more commonly associ-
ated with the plasma membrane. Ion homeostasis and solute
transport comprises three groups of candidate genes relat-
ing to excitotoxicity, calcium homeostasis, and water and sol-
ute transport, respectively.
Excitotoxicity, the excessive signaling of glutamate recep-
tors, is a key pathogenic mechanism proposed in ALS, and
is aggravated by a weakening of inhibitory synaptic events
Table 3: Comparison of expression ratios in motor cortex and spinal cord
Expression Ratios
Gene Symbol UniGene ID Motor Cortex Spinal Cord Comparison
AQP1 Hs.76152 2.52 2.84 ==
MT2A Hs.418241 2.43 4.66 =
SLC14A1 Hs.101307 2.15 1.91 ==
ANXA2 Hs.511605 2.06 4.49 =
MT1X Hs.374950 2.02 1.99 ==
FCGBP Hs.111732 2.00 3.14 =
DSCR1L1 Hs.440168 0.49 0.49 ==
PCP4 Hs.80296 0.49 0.60 ==
SCG5 Hs.156540 0.48 0.58 ==
UCHL1 Hs.518731 0.48 0.48 ==
GABRA1 Hs.175934 0.47 0.56 ==
EGR1 Hs.326035 0.46 0.42 ==
OLFM1 Hs.522484 0.43 0.50 ==
VSNL1 Hs.444212 0.35 0.38 ==
SNAP25 Hs.167317 0.31 0.82 <>
MDH1 Hs.526521 0.41 0.68 <>
CHN1 Hs.380138 0.42 0.71 <>
EIF4A2 Hs.478553 0.45 0.98 <>
RTN1 Hs.368626 0.46 0.71 <>
ATP5A1 Hs.298280 0.48 1.13 <>
NDUFA4 Hs.50098 0.48 0.73 <>
PCSK1 Hs.78977 0.39 1.73 <>
CHGB Hs.516874 0.39 1.65 <>
Expression ratios for candidate genes identified in the present report (Motor Cortex) are compared to those found by Dangond et al. [4] (Spinal 
Cord), giving a correlation coefficient of r = 0.85. Spinal cord data were retrieved from the Gene Expression Omnibus Database (GEO, series 
GSE833) and processed as described in the Methods section.
== both tissues give the same result, differing ≤1.5-fold
= both tissues give the same result, differing >1.5-fold
<> both tissues give different results (up- vs. down-regulation or deregulation vs. constancy, defining constancy as a ≤1.5-fold deregulation)Page 12 of 26
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BMC Genomics 2007, 8:26 http://www.biomedcentral.com/1471-2164/8/26mediated by the GABAA receptor. Alterations of its com-
position, such as the depletion of its GABRA1 subunit
found in this study, was previously demonstrated in
human motor cortex of ALS patients and is associated
with heightened excitability [26]. Increased excitability,
and hence exacerbated excitotoxicity, may also derive
from the reduced expression of ATP1A3, KCNC2, and
SLC12A5. Mutations of the plasma-membrane Na+/K+
pump ATP1A3 have been linked to rapid-onset dystonia-
parkinsonism [27]. Moreover, ATP1A3 expression is
reduced in SOD1(G93A) FALS mice [28] and in motone-
urons of Wobbler mice, a genetic model of spinal-cord
motoneuronal degeneration, with progesterone treatment
restoring both, ATP1A3 mRNA expression and viability of
motoneurons [29]. KCNC2 regulates the voltage-depend-
ent potassium ion permeability of excitable membranes,
and its decreased expression may lead to decreased potas-
sium conductance and hence delayed repolarization of
Table 4: Comparison of expression ratios in patients with SALS and Alzheimer's disease
Expression Ratios
Gene Symbol UniGene ID SALS AD Comparison
AQP1 Hs.76152 2.52 1.62 =
CEBPD Hs.440829 2.52 1.77 ==
SERPINA3 Hs.534293 2.38 2.40 ==
SLC14A1 Hs.101307 2.15 2.20 ==
SLC12A5 Hs.21413 0.50 0.40 ==
CYCS Hs.437060 0.49 0.52 ==
DSCR1L1 Hs.440168 0.49 0.39 ==
NRGN Hs.524116 0.49 0.41 ==
PCP4 Hs.80296 0.49 0.32 =
ATP5A1 Hs.298280 0.48 0.61 ==
CAP2 Hs.132902 0.48 0.52 ==
GNAS Hs.125898 0.48 0.48 ==
NDUFA4 Hs.50098 0.48 0.62 ==
UCHL1 Hs.518731 0.48 0.67 ==
YWHAH Hs.226755 0.48 0.53 ==
PNMA2 Hs.521466 0.46 0.56 ==
RTN1 Hs.368626 0.46 0.37 ==
OLFM1 Hs.522484 0.43 0.55 ==
RTN4 Hs.429581 0.43 0.75 =
CHN1 Hs.380138 0.42 0.50 ==
MDH1 Hs.526521 0.41 0.54 ==
BEX1 Hs.334370 0.40 0.63 =
NEF3 Hs.458657 0.38 0.28 ==
VSNL1 Hs.444212 0.35 0.26 ==
ENC1 Hs.104925 0.34 0.74 =
NEFL Hs.521461 0.32 0.35 ==
SNAP25 Hs.167317 0.31 0.59 =
MT2A Hs.418241 2.43 1.31 <>
MT1E Hs.534330 2.29 1.32 <>
MT1G Hs.433391 2.19 1.36 <>
ANXA2 Hs.511605 2.06 1.45 <>
MT1X Hs.374950 2.02 1.39 <>
ATP1A3 Hs.515427 0.49 1.46 <>
ATP6V1A Hs.477155 0.49 0.78 <>
EGR1 Hs.326035 0.46 1.63 <>
EIF4A2 Hs.478553 0.45 0.75 <>
NSF Hs.431279 0.45 1.01 <>
CHGB Hs.516874 0.39 2.37 <>
Expression ratios for candidate genes identified in the present report (SALS) are compared to those found for data by Blalock et al. [18] for 
Alzheimer's disease (AD), giving a correlation coefficient of r = 0.696. AD data were retrieved from GEO (series GSE1297) and processed as 
described in the Methods section.
== both tissues give the same result, differing ≤1.5-fold
= both tissues give the same result, differing >1.5-fold
<> both tissues give different results (up- vs. down-regulation or deregulation vs. constancy, defining constancy as a ≤1.5-fold deregulation)Page 13 of 26
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in other voltage-gated potassium channels can lead to
hyperexcitability and hypersensitivity to oxidative stress
[30]. SLC12A5 encodes the neuronal isoform of the potas-
The interplay of cell types and pathways in SALS pathologyFigure 7
The interplay of cell types and pathways in SALS pathology. Combining pathways and candidate genes differentially 
expressed in the motor cortex of SALS patients reveals a complex interplay of cellular processes and cell types. Candidate 
genes corresponding to major pathways discussed in the main text are color-coded, placed in the cell type(s) where they most 
likely exert their influence, and their individual up- ( ) or down-regulation ( ) is indicated. Genes EIF4A2, GNAS, and NAP1L5 
are left out for clarity.
Å ÆPage 14 of 26
(page number not for citation purposes)
BMC Genomics 2007, 8:26 http://www.biomedcentral.com/1471-2164/8/26sium-chloride cotransporter family. During early develop-
ment, increased expression of SLC12A5 lowers the
intraneuronal chloride concentration below its electro-
chemical equilibrium and allows GABA to act as an inhib-
itory neurotransmitter. Conversely, a switch of GABA
action from inhibitory to excitatory has been proposed as
a mechanism contributing to excitotoxicity in injured
neurons. Indeed, down-regulation of SLC12A5 expression
together with GABAA receptor-mediated excitation occurs
after in-vivo axonal injury [31], and mouse SLC12A5
knockouts suffer severe motor deficits and immediate
postnatal death by asphyxiation [32].
Calcium homeostasis and calcium-binding proteins are crit-
ical to preventing motoneuron death in ALS, and with
PVALB, DSCR1L1, NRGN, and PCP4 we found four genes
down-regulated in the ALS motor cortex that moderate the
impact of intracellular calcium release. There is disagree-
ment whether the calcium buffer PVALB represents a
marker of motoneurons resistant to ALS-related cell death
[33,34], but its reduction would likely increase cell death
at the elevated calcium concentration typical of ALS [35].
Similarly, DSCR1L1 is an inhibitor of calcineurin [36], a
mediator of many cellular responses, including apoptosis
[37]. Depletion of the two calmodulin-binding proteins
NRGN and PCP4, involved in moderating calmodulin-
mediated calcium signaling, would further reduce resist-
ance to calcium-mediated toxicity [38,39].
Water and solute transport is represented by the up-regula-
tion of AQP1 and SLC14A1. Both, AQP1 and SLC14A1,
experience up-regulation with age and by hypertonicity
[40], and like AQP1 the urea transporter SLC14A1 may
also function as an efficient water transporter [41]. Their
joint up-regulation found in this study is indicative of dis-
turbed ion and water homeostasis in the motor cortex of
SALS patients. The water transporter AQP1 in particular is
of interest through its association with synaptic vesicles
and participation in their swelling in cells outside the cen-
tral nervous system [42].
Protein modification and turnover
Protein modification and turnover are essential to motoneu-
ron survival, resulting in the selective death of motoneu-
rons upon chemical inhibition of the proteasome
complex [43], which we detected as down-regulated in
SALS samples by pathway-based analysis of our micro-
array data, thus stressing a role of disturbed protein turn-
over in ALS pathogenesis. Indeed, the progressive
accumulation of polyubiquitinated protein conjugates,
indicating a failure of proteasomal turnover, is a consist-
ent feature of many neurodegenerative diseases [44],
including ALS [1]. In line with this we also observed the
down-regulation of UCHL1, a neuron-specific ubiquitin
carboxy-terminal hydrolase-1, which also displays a sec-
ondary dimerization-dependent ubiquitin-ligase activity
and represents up to 2% of total soluble brain protein
[45]. A point mutation affecting the ligase activity of
UCHL1 has been linked to Parkinson's disease [46], while
an internal 42-amino-acid deletion in UCHL1 is responsi-
ble for murine gracile axonal dystrophy, which is charac-
terized by axonal degeneration and formation of spheroid
bodies in nerve terminals [47]. The latter phenotype and
the observation of poly-ubiquitinated aggregates in ALS
create a tantalizing link between the hydrolase activity of
UCHL1 and the depletion of UCHL1 mRNA in the motor
cortex of SALS patients. Up-regulation of SERPINA3, a ser-
ine protease inhibitor enriched in neurofilament con-
glomerates of ALS motoneurons [48], can be seen in the
same light and has been associated with other neurode-
generative diseases. In Alzheimer's disease, for instance,
its astrocytic expression is elevated [49] and exacerbates
the accumulation of protein aggregates [50]. SERPINA3
also has other effects, however, including protection
against microglia [51].
Cytoskeleton
The cytoskeleton is critical for neuronal maintenance and
plasticity, neurite outgrowth, axonal caliber and trans-
port. Our analysis reveals the alteration of two major com-
ponents of the neuronal cytoskeleton in the ALS motor
cortex at the mRNA level, showing a general down-regula-
tion of microtubules by pathway-based analysis and
deregulation of two genes encoding tubulin beta
(TUBB2A, TUBB6), as well as decreased expression of all
three neurofilament subunits (NEFL, NEF3, NEFH). A
depletion of microtubules and neurofilaments has delete-
rious effects on motoneurons, according to our present
understanding of their role in ALS pathogenesis [1].
Impaired microtubule-based axonal transport causes
related motoneuropathies and is the earliest detectable,
presymptomatic abnormality in SOD1-mutant FALS
mice. What is more, defects in microtubule-associated
motor proteins cause ALS-related human motoneuropa-
thies, such as Charcot-Marie-Tooth disease 2A [52] and
hereditary spastic paraplegia [53], and are responsible for
ALS phenotypes in Drosophila [54] and mouse [55]. The
role of neurofilaments (NFs) in ALS is still controversial,
despite a substantial body of research addressing the sub-
ject [1]. NF assemblies have been suggested as a possible
impediment to axonal transport, either as its aberrantly
crosslinked cargoes or in stationary aggregates, and even
disturbing the stoichiometric balance between NF subu-
nits can lead to ALS-like morphology and death of
motoneurons. However, despite a raised incidence of
mutations in NF genes in ALS subjects, a comprehensive
study has excluded mutations in NF genes as a primary
cause for ALS [56]. Moreover, ALS pathogenesis also
progresses without axonal neurofilaments [57], and over-
expression of NEFH prolongs survival of SOD1-transgenicPage 15 of 26
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act as an abundant buffer for otherwise deleterious proc-
esses, such as actions of SOD1 gain-of-function mutants
[58] or aberrant tyrosine nitrosylation or phosphorylation
[1,59,60]. The down-regulation of all three NF subunits
observed in this study would be detrimental according to
either interpretation of NF involvement in ALS pathology,
first by interfering with their stoichiometric balance and
second by depleting their availability as a potential buffer
for aberrant enzymatic activities.
Neuronal maintenance and signaling
Changes in Neuronal maintenance and signaling, detected
by gene-based analysis of our microarray data, comprise
only down-regulated genes and tie in with observations
for disturbed signaling in the motor cortex of sporadic,
non-SOD1-linked ALS [12,13]. Depleted are general pro-
moters of neurodifferentiation and axonal and dendritic
maintenance (CAP2, ENC1, MLLT11, OLFM1, VSNL1),
with clear implications for neuronal survival, but also sev-
eral inhibitors of differentiation and promoters of cell
proliferation (BEX1, CHN1, RTN1, RTN4, NPTN), whose
role in ALS pathogenesis is ambiguous. Four additional
genes (ATP6V1A, NSF, SNAP25, SYT13) encode proteins
regulating synaptic vesicle processing and exocytosis,
processes highly relevant to ALS pathology [1]. While
most of the above genes are known to be expressed in
multiple cell types, some of them (CHN1, NPTN,
SNAP25, OLFM1, VSNL1) are neuron-specific. Impor-
tantly, we had ensured selecting patient material that
exhibited good histological integrity of the motor cortex
(see Figure 1), thus minimizing the possibility that obser-
vations for neuron-specific genes would reflect the loss of
motoneurons typical of ALS.
MLLT11 expression is up-regulated in differentiated corti-
cal neurons, and its ectopic expression in embryonic kid-
ney cells triggers the expression of neuronal markers [61].
OLFM1, a secreted glycoprotein, is also strongly expressed
in cerebral cortex [62,63] and has been implicated in neu-
ral crest development in birds [64] and neurogenesis in
Xenopus [65]. ENC1 is a matrix protein expressed almost
exclusively in the brain, whose overexpression induces
neuronal process formation and whose knock-down
inhibits neurite development [66]. Similarly, the calcium-
dependent action of VSNL1 has been linked to the promo-
tion of axonal differentiation and to axonal plasticity [67].
The multifunctional protein encoded by CAP2 links the
actin cytoskeleton and cAMP signaling, and might there-
fore facilitate intracellular signal transduction events, den-
dritic plasticity and synaptic membrane recycling [68,69].
Amongst the down-regulated inhibitors of neurodifferen-
tiation in the SALS motor cortex are BEX1, a promoter of
cell proliferation [70], and RTN1 and RTN4, two mem-
bers of the reticulon family thought to play an important
role in the regulation of neuronal regeneration. RTN4, in
particular, is a potent neurite outgrowth inhibitor and has
been shown to inhibit the regeneration of severed axons
in the mammalian central nervous system [71]. NPTN
encodes a protein involved in cell-cell interactions that
inhibits neurite outgrowth from dorsal root ganglion and
forebrain neurons [72]. Finally, CHN1 encodes the Rac
GTPase activating protein alpha-1-chimerin, which medi-
ates the pruning of dendrites in response to synaptic activ-
ity [73].
ATP6V1A is a subunit of the vacuolar proton pump V-
ATPase, which generates a proton gradient across the
membrane of maturing synaptic vesicles, required for the
accumulation of neurotransmitters within them [74].
SNAP25 is a mediator of axonal repair, a regulator of cal-
cium signaling, and a component of the NSF-binding
SNARE complex, essential to vesicle fusion and recycling
[75], and therefore has an impact on at least three proc-
esses critical to ALS pathogenesis. Like alsin, a likely regu-
lator of endosome dynamics and a causative gene for
juvenile forms of ALS [1], SNAP25 is also involved in
endosome recycling [76], creating a fourth, albeit tenta-
tive, link of SNAP25 to ALS pathogenesis. SYT13, like
SNAP25, participates in neurite outgrowth and axonal
repair, and unlike usual synaptotagmins binds to cellular
membranes in a Ca2+-independent fashion to facilitate
membrane fusion and exocytosis [77]. It is unclear
whether SYT13, like other synaptotagmins, does so by
interaction with SNAP25. Following membrane fusions
the down-regulated NSF, a key component of internal and
exocytotic vesicle transport [78], facilitates the ATP-
dependent recycling of SNARE proteins, such as SNAP25.
Defense signaling
Defense signaling has been implicated in ALS pathogenesis
by numerous studies showing inflammatory and immune
responses [1], and linking the detection of IgG in ALS
motoneurons to neuronal apoptosis [79]. Additional evi-
dence is provided by the detection of IgG in motoneurons
of the spinal cord and in pyramidal cells within the motor
cortex of ALS patients [80-82] and by the ability of IgG
from patients with ALS to induce apoptotic neuronal cell
death [79,83,84]. Importantly, IgG purified from ALS
patients was found to induce synaptic transmission
through interaction with presynaptic membranes, relating
autoantibodies in ALS to excitotoxicity [85]. In the present
study defense signaling comprises the only up-regulated
GO categories in the SALS motor cortex, and is repre-
sented by numerous candidate genes, whose differential
expression likely promotes (FCGBP, YWHAH, ANXA2,
S100A8, EDN1, CEBPD) or suppresses (EGR1, metal-
lothioneins) inflammatory responses, respectively.
Down-regulation of PNMA2, whose product is a target ofPage 16 of 26
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of a PNMA2-autoantibody-associated encephalitis patient
with ALS symptoms, who presented with inflammation in
cortex and spinal-cord grey matter [86,87]. With a sus-
pected contribution of inflammatory responses to ALS
pathogenesis, this suggests the targeting of PNMA2 by
neurodegenerative autoimmune responses, leading to a
depletion of PNMA2-positive cells. In line with this, the
up-regulated FCGBP, encoding an IgG-Fc binding protein,
may be involved in immune protection and inflammation
[88], and shows elevated serum levels in patients with
autoimmune disorders [89]. Elevated levels of FCGBP
could therefore contribute to ALS pathogenesis by facili-
tating autoimmune and neuroinflammatory responses.
Up-regulation of CEBPD, encoding a transcription factor
of cytokines and other pro-inflammatory response genes,
elevated in the brain of Alzheimer's disease patients and
itself induced by inflammatory stimuli, ties in with this
assumption [90]. Similarly, the down-regulation of
YWHAH, a gene linked to schizophrenia that encodes a
transcriptional activator of the glucocorticoid receptor
[91] and therefore of anti-inflammatory responses, can
also be predicted to aggravate neuroinflammation. The
up-regulated candidate genes ANXA2 and S100A8 encode
two Ca2+-modulated proteins expressed in microglia and
are implicated in the intracellular and extracellular regula-
tion of inflammatory responses [92,93]. ANXA2 pro-
motes generation of plasmin on the cell surface [94], a
process linked to excitotoxin-induced neurodegeneration
[95]. S100A8 mediates inflammatory responses, such as
the induction of chemokines, and has been linked to the
reduction of cell junction proteins and of membrane
integrity [96].
The multifunctionality of EDN1 and EGR1 make the con-
sequences of their differential expression in the SALS
motor cortex ambiguous. For instance, the up-regulated
EDN1, encoding a pro-inflammatory vasoconstrictor pep-
tide, exerts a variety of ALS-aggravating effects, including
axonal degeneration [97], impairment of water homeos-
tasis, heightened sensitivity to hypoxic stress [98], and
increased excitotoxicity [99]. However, neuron-specific
EDN1-knockout mice show elevated sensitivity to pain
[100], and EDN1 expression in astrocytes is required for
their survival under oxidative stress [101]. Moreover, the
hypoxia-inducible EDN1 promotes angiogenesis, reduc-
ing the possible effects of hypoxia-related oxidative stress
[101,102], amongst other mechanisms by activation of
the vascular endothelial growth factor. On the other hand,
down-regulation of EGR1, a master switch of inflamma-
tory responses prompted by oxidative stress [103], coun-
teracts angiogenesis, thus increasing hypoxic conditions,
but has an anti-inflammatory effect. It is important to
note that the up-regulated ANGPTL4 (see Glycolysis
above) and the down-regulated EGR1, two inducers of
angiogenesis [6,104], represent a positive and a negative
target of the hypoxia-induced peroxisome-proliferator-
activated receptor gamma [103,105], respectively. There-
fore the differential expression of EGR1, ANGPTL4, and
EDN1 indicates hypoxic conditions in the SALS motor
cortex, tying in with a predisposition for ALS by mutation
of angiogenin in man [106] and of vascular endothelial
growth factor in mouse [107].
Indicating protective responses in the SALS motor cortex,
we observed the up-regulation at the mRNA level of met-
allothioneins (MT1E, MT1G, MT1L, MT1M, MT1X,
MT2A), neuroprotective, anti-oxidant stress-response pro-
teins induced by metal ions, cytokines, and other stress
stimuli [108]. Metallothioneins of the MT1 and MT2 fam-
ilies are expressed in astrocytes, and are increased in spinal
cord of ALS patients and in transgenic mutant-SOD1
mice, where their experimental reduction significantly
reduces survival. Importantly, endogenous MT1 and MT2
are undetectable in pure motoneuron cultures, which can
be protected against oxidative stress by experimental MT1
overexpression [109], indicating the importance of metal-
lothionein-mediated protection normally provided by
astrocytes.
Orphan genes
Orphan genes, candidate genes with wide-ranging func-
tions (EIF4A2) or without sufficient functional character-
ization (NAP1L5, GNAS), can only be associated
tentatively with major deregulated pathways identified in
this study, and were omitted from Figure 7. The down-reg-
ulated translation initiation factor EIF4A2 is interchange-
able with EIF4A1 for the initiation of translation in
general, and induces neural folding during embryonic
development [110]. Interestingly, EIF4A2 has also been
linked to type-2 diabetes and in rat cells appears to sup-
press insulin expression [111]. Its down-regulation, like
that of CHGB, SCG5, and PCSK1, would therefore lead to
elevated insulin levels and hence reduced glucose availa-
bility (see Glycolysis above). The down-regulated
NAP1L5 is an imprinted and largely uncharacterized gene,
highly expressed in brain [112]. NAP1L5 has sequence
similarity to NAP1, a cytoplasmic-nuclear shuttle protein
for histones, that has large-scale effects on gene expression
by chromatin restructuring [113]. The GNAS gene is also
down-regulated and, like NAP1L5, is imprinted [114].
Alternative first exons for GNAS transcripts lead to distinct
products, which in human have been linked to osteodys-
trophy and pseudohypoparathyroidism phenotypes,
while in mouse GNAS heterozygous mutants show meta-
bolic abnormalities and insulin hypersensitivity (see Gly-
colysis above).Page 17 of 26
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Global reduction of energy supply
Pathway-based and gene-based analyses show a general
down-regulation of nuclear genes encoding mitochon-
drial components in the motor cortex of ALS patients.
Although at first glance tying in with ALS-related mito-
chondrial dysfunction, this observation is at odds with the
heightened level of oxidative stress typical of ALS. Numer-
ous studies have characterized oxidative stress as a general
inducer of nuclear genes that boost replication, mainte-
nance and repair of mitochondria, as compensatory
action for stress-related mitochondrial damage and death
(see [23]). The down-regulation observed in the present
study suggests alternative signaling to achieve a targeted
depletion of mitochondrial components in the SALS
motor cortex, which might therefore be a cause rather
than a consequence of ALS pathology.
As for mitochondrial energy supply, pathway-based and
gene-based analyses have independently indicated a
reduction in glycolytic activity. Experimental inhibition of
glycolysis in an FALS cell-culture model diminishes cell
viability, suggesting that ALS-related mitochondrial dys-
function critically reduces cellular ATP supply [115],
while hypoglycemia is a strong inducer of oxidative stress,
even in the absence of such aggravating factors [116].
Now our results indicate that reduction in glycolytic
energy supply is in itself a factor contributing to ALS
pathology, suggesting as one overriding cause of ALS-
related neuronal cell death the depletion of intracellular
ATP levels by a combined reduction of the TCA cycle, oxi-
dative phosphorylation and glycolysis.
Reduced intracellular ATP levels lead to increased suscep-
tibility to cell death upon oxidative [117] and excitotoxic
[118] stress, and would be particularly detrimental to the
survival of neurons, as the re-establishment of Ca2+ gradi-
ents and of general ion homeostasis following neuronal
signaling is highly ATP-dependent. As an aggravating fac-
tor, coordinated Ca2+ signaling is facilitated in neurons by
strategic positioning of mitochondria near endoplasmic-
reticulum Ca2+-release sites [20]. Therefore, reduced avail-
ability of ATP would lead to a downward spiral of an ina-
bility to remove intracellular Ca2+, Ca2+-induced
mitochondrial production of reactive oxygen species, and
additional depletion of mitochondrial ATP supply.
The importance of addressing all cell types in ALS therapy
During our expression analysis of the motor cortex we
identified several candidate genes, such as AQP1, CEBPD,
SERPINA3, and the MT1 and MT2 family members, which
are exclusively expressed in non-neuronal cells. Particu-
larly in the analysis of excitotoxicity and defense signal-
ing, involving astrocytes and microglia, and in the
interplay of inflammatory versus anti-inflammatory and
of cell-death versus cell-rescue responses, the importance
of different cell types involved in ALS pathology becomes
apparent. The survival of motoneurons is highly depend-
ent on their cellular environment, which is to a large
majority made up of non-neuronal cells [119]. Data on
the interaction of neurons with glial cells in the context of
ALS are still patchy, but there is a growing understanding
that non-neuronal cells have a fundamental role to play in
the pathogenesis of neurodegenerative diseases [119].
Our data indicate a general increase of microglial activity
and immune responses, likely aggravating ALS disease
symptoms. It is known, however, that the role of micro-
glia in neuropathies extends beyond immune responses
alone. Only recently, activated microglia have been recog-
nized to hypersensitize sensory neurons, and their role in
motoneuronal excitotoxicity still remains to be investi-
gated [120]. Moreover, our data show mixed signals from
astrocytes, comprising inflammatory and anti-inflamma-
tory responses, which have to be evaluated on an individ-
ual basis and might be modulated to slow disease
progression. Astrocytes might have significant impact on
the excitotoxicity and the oxidative stress responses
detected by our study, as they are in close interaction with
motoneurons and neuronal synapses, and themselves
express all the components required for Ca2+-responsive
vesicular glutamate release [121,122].
Perspectives for ALS therapy
In the absence of effective treatments for ALS, the search
for potential therapeutics continues. Like Riluzole, the
only approved ALS treatment to date, the vast majority of
drugs currently considered for clinical trials are based on
animal models with SOD1-mutant background (85% in a
recent survey [123]). Only an estimated 2% of ALS cases,
however, are linked to SOD1, and resulting treatments
might therefore, similar to Riluzole, have limited value as
general ALS therapies. However, several candidate com-
pounds for ALS therapy [123] address aspects of SOD1
mutants, such as oxidative stress, impaired metal binding,
and defects in protein folding, that we have also identified
as affected in the motor cortex of sporadic, non-SOD1-
linked patients.
A successful general therapy of ALS will have to consider
the interplay and individual roles of different pathways
and cell types in pathogenesis. The comprehensive analy-
sis described here provides a full molecular portrait of the
changes occurring in the motor cortex of SALS patients
and provides new leads for the development of effective
ALS therapies. Indeed, for the manipulation of many of
the genes and pathways implicated by this study, experi-
mental or therapeutic drugs, not yet discussed in the con-
text of ALS, are already available [124,125]. Moreover, our
findings suggest that several drugs, currently used to treat
unrelated diseases, might be of benefit to ALS patients.Page 18 of 26
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employed against diabetes and pulmonary hypertension
[126]. The widely used anti-inflammatory drug ibuprofen
is an antagonist of isoleucin-1β and of its downstream tar-
get SERPINA3 [127]. GABA antagonists such as zopiclone,
used to treat insomnia, are of potential benefit to
GABRA1-related excitotoxicity [128]. Significantly, symp-
tom progression was stopped in a patient presenting with
anti-PNMA2-related motoneuron degeneration by a com-
bination of corticosteroids, intravenous immunoglobulin
and antiepileptic drugs [86]. Similarly, and although it is
clear from SOD1-linked FALS that all the alterations
detected in ALS can have a common root and are therefore
interrelated, therapy of ALS might also require combined
medication to combat disease progression at multiple
fronts. Many of the potential targets of this battle have
been outlined by this study.
Methods
Characteristics of subjects
Two groups of patient samples, consisting of eleven SALS
and nine control subjects, were used in this study. Fresh-
frozen samples of human motor cortex (precentral-gyrus
sections) were obtained from the NICHD Brain and Tis-
sue Bank for Developmental Disorders under contracts
NO1-HD-4-3368 and NO1-HD-4-3383 and selected for
post-mortem intervals (PMI) prior to freezing not exceed-
ing 24 hours. Additionally, two patient samples were
obtained as total RNA from a commercial source
(Ambion, Inc.). All sample material is certified to have
been obtained following international ethical guidelines
and with prior consent from a fully informed donor or a
member of the donor's family. All disease samples were
cases of spontaneous ALS, with a mean patient age of 68.2
± 7.6 years. Control samples had a mean patient age of
68.7 ± 11.0 years and were selected for matching age and
for causes of death unrelated to ALS or other neurological
disorders. Detailed information related to source code,
age, sex, race, and storage of patient samples is given in
Table 1.
Sample preparation
Individual slices of 10 μm were produced from tissue sam-
ples at -20°C by a Leica CM1510S cryostat (Leica Micro-
systems) and stored at -80°C until further processing. Two
slices per sample were stained by hematoxylin/eosin
staining (Bio Optica) and for Nissl substance (with a
microfiltered solution of cresyl violet, Sigma), respec-
tively, to assess integrity of cellular and tissue morphol-
ogy. Individual slices were used for in-situ hybridization
and immunofluorescence (see below). Ten adjacent slices
per sample were pooled and used for RNA extraction with
Trizol (Invitrogen) following the manufacturer's standard
protocol, followed by confirmation of RNA integrity by
agarose gel electrophoresis.
Microarray processing and data extraction
Complementary RNAs (cRNAs) labeled with Cy5-CTP
(Perkin-Elmer) were synthesized from 1 μg of total RNA
of each sample using the Low RNA Input Fluorescent Lin-
ear Amplification Kit (Agilent Technologies) following
the manufacturer's protocol. A reference cRNA, labeled
with Cy3-CTP (Perkin-Elmer), was synthesized from 1 μg
of sample D2 RNA. Aliquots (750 ng) of Cy3 and Cy5
labeled cRNA targets were co-hybridized on Whole
Human Genome Oligo Microarrays (Agilent Technolo-
gies). Microarray hybridization and washing were per-
formed using reagents and instruments (hybridization
chambers and rotating oven) as indicated by the manufac-
turer (Agilent Technologies).
Microarrays were scanned at 10-μm resolution using a
GenePix Personal 4100A microarray scanner and the
GenePix Pro 6.0 acquisition and data-extraction software
(Molecular Devices, Corp.). Raw data were processed and
analyzed with Acuity 4.0 (Molecular Devices, Corp.) and
GeneSpring 7.2 (Agilent Technologies). To remove unreli-
able data, all genes from all samples were filtered for qual-
ity to include only probe data fulfilling all of the following
criteria: the spot had < 3% of saturated pixels at 635 and
532 nm; the spot was not flagged "bad", "not found" or
"absent"; the spot had relatively uniform intensity and
uniform background (Rgn R2 635/532 > 0.6); the spot was
detectable well above background (signal-to-noise ratios
at 635 or 532 nm > 3). Filtering data by quality control cri-
teria short-listed 19,431 genes as our complete data set for
Lowess normalization and subsequent analyses, out of a
total of 44,233 probes (including control and alignment
probes) present on the microarrays. The microarray data
have been deposited in the Gene Expression Omnibus
(GEO) database [129] under accession no. GSE4595.
Pathway-based microarray analysis
To analyze the gene expression changes in the context of
known biological pathways we used the Gene Map Anno-
tator and Pathway Profiler (GenMAPP) 2.0 software pack-
age [130].
Input data for GenMAPP analysis were unique probe
identifiers, corresponding UniGene cluster IDs, an aver-
age fold-change and an uncorrected P value (Welch's t-
test) diseased vs. control for all 19,431 short-listed genes
of our complete data set. If a UniGene cluster ID was rep-
resented by multiple probes, the probe carrying the lowest
(most significant) uncorrected P value was used for path-
way-based comparison with spinal-cord data [4] (see
below). GenMAPP dynamically links gene-expression
data to the gene ontology (GO) hierarchy of biological
processes, cellular components and molecular functions
[131]. For each of the GO categories in the hierarchy
(nodes), and including all the genes in its child nodes,Page 19 of 26
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rion (≥ 1.2-fold-change in our analysis, as recommended
by [132] and [133]). From the total number of genes ana-
lyzed, the number of genes in a category and the corre-
sponding numbers of genes meeting the queried criterion
a z score is calculated, which indicates the non-random-
ness (for high, positive z scores) of the proportion of
genes meeting the criterion. Additionally, a corrected P
value is calculated through permutation analysis (2000
permutations) of the data, followed by Westfall-Young
adjustment for multiple hypothesis testing. Permutation
analysis sets limits to the resolution of extremely signifi-
cant events, so that the P value for all events with an
uncorrected P < 0.0005 equals zero. Only nodes with pos-
itive z scores and a corrected P < 0.05 were considered in
our analysis, with a higher z score indicating greater signif-
icance between nodes of identical P value.
Gene-based microarray analysis
Of our quality-filtered data set of 19,431 genes, those with
an average change greater than twofold were screened by
a two-sided one-way ANOVA using Welch's t-test (with a
Kolmogorov-Smirnov-test P value of 0.38 or above indi-
cating a normal distribution of tested values), followed by
the Benjamini and Hochberg False Discovery Rate proce-
dure as a multiple testing correction. Genes with a cor-
rected P value < 0.05 were selected as differentially
expressed candidate genes. All candidate probe sequences
were tested against the NCBI nucleotide database
(November 2005) by BLASTN to update their annotations
and confirm the specificity of each probe.
Quantitative RT-PCR
Sample total RNA (2 μg) was reverse transcribed with the
Protoscript reverse transcription kit (New England
Biolabs) using the VN(dT)23 primer as recommended by
the manufacturer. As a standard for relative RNA quantifi-
cation (Standard cDNA), ten equivalent reactions using 2
μg pooled RNA from healthy control samples (222 ng
each) were performed and the resulting cDNAs precipi-
tated and resuspended in 50 μl water each. As a negative
control for cDNA quantification, a further reaction using
2 μg of pooled RNA was performed, in which the reverse
transcriptase was replaced by water. All cDNAs were tested
by conventional PCR with primers for glyceraldehyde-3-
phosphate dehydrogenase (New England Biolabs), using
1/50 of each cDNA (the equivalent of 40 ng total RNA).
Quantitative RT-PCR (qRT-PCR) amplifications were per-
formed with a LightCycler (Roche Molecular Biochemi-
cals) using the same starting amount and LightCycler®
FastStart DNA MasterPLUS SYBR Green I reagents in a
standard volume of 20 μl. Real-time detection of fluori-
metric intensity of SYBR Green I, indicating the amount of
PCR product formed, was measured at the end of each
elongation phase. Fluorescence values measured in the
log-linear phase of amplification were considered using
the second-derivative-maximum method of the LightCy-
cler Data Analysis software (Roche Molecular Biochemi-
cals). Relative quantification was performed using serial
dilutions of pooled Standard cDNA (the equivalent of 80,
40, 20, 10 and 5 ng total RNA, respectively, run in dupli-
cate) to provide a standard curve for each run. For all
experiments, the standard curve had an error of below 5%
and extended over the relative quantities of all individual
samples.
Candidate genes whose differential expression was tested
by gene-specific qRT-PCR analysis were parvalbumin and
the metallothioneins MT1B, MT1E, MT1G, MT1L, MT1M,
MT1X and MT2A. Differences in the quantity of starting
material were compensated by normalization with the
housekeeping genes beta-2-microglobulin (B2M) and
ribosomal protein L19 (RPL19). The primers used are
detailed below. Normalized fold-changes between dis-
eased and healthy samples were calculated and tested by a
two-tailed Mann-Whitney U-test (not assuming equal var-
iances).
In-situ hybridization
cDNAs corresponding to four mRNAs were synthesized by
PCR from human brain RNA using specific forward and
reverse primers. PCR fragments were subcloned into
pCR4Blunt-TOPO vector (Invitrogen) and the orientation
of the insert was determined by sequencing. Following
linearization of plasmids by restriction endonucleases,
riboprobes containing Cy3-CTP (sense) or Cy5-CTP (anti-
sense) (Perkin-Elmer) were synthesized by T3 and T7
polymerase, respectively, using the MAXIscript In Vitro
Transcription Kit (Ambion, Inc.). The in-situ hybridization
procedure was performed as previously described [134].
Fluorescent hybridization signals were obtained by scan-
ning sections at 5-μm resolution using a GenePix Personal
4100A scanner (Molecular Devices, Corp.). No signal was
detected in control brain sections hybridized with the
sense riboprobes or pretreated with RNase before hybrid-
ization with the antisense probes. Evaluation of hybridi-
zation signals were obtained by using a computer-assisted
image analysis system and the Photoshop 7.0 software
(Adobe Systems, Inc.).
Immunoblots
Protein was extracted from human motor-cortex samples
using standard methods. Following SDS-PAGE separation
on 10–12% gels and semi-dry protein blotting (transfer
buffer 10 mM NaHCO3, 3 mM Na2CO3, 20% methanol,
pH 9.9) to nitrocellulose Hybond membranes (Amer-
sham Pharmacia Biotech), blots were blocked (0.1%
Tween, 3% milk PBS), incubated with the appropriate pri-
mary antibody at 4°C over-night, and following threePage 20 of 26
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body. Primary antibodies (all Santa Cruz Biotechnology,
Inc.) were rabbit antibodies ANXA2 (SC-9061), AQP1
(SC-20810), and CANX (SC-11397), and goat antibody
NRGN (SC-18336), all at 1:100 dilution. As HRP-conju-
gated secondary antibodies (all Amersham Pharmacia
Biotech) we applied a 1:4000 dilution of anti-rabbit anti-
body for detection of ANXA2, AQP1, and CANX, and of
anti-goat antibody for NRGN. Immunoblots were visual-
ized using the Enhanced Chemiluminescence System
(Amersham Pharmacia Biotech). Band intensities were
determined as background-corrected volume measure-
ments using the ImageQuant TL software (Amersham
Pharmacia Biotech), were equalized using CANX as a
loading reference (which has not been linked to ALS and
in our microarray analysis showed an mRNA ratio dis-
eased vs. control of 0.97), and were subjected to statistical
analysis using a two-tailed, heteroscedastic Student's t-test
in Excel (Microsoft Corp.).
Primers
The following forward (FP) and reverse (RP) primers were
used for qRT-PCR analysis: PVALB (GenBank Accession
No: NM_002854, forward primer (FP): 5'-acgctgaggacat-
caagaagg-3', 5'-caattttgccgtccccatc-3), reverse primer (RP):
MT1B (GenBank Accession No.: NM_005947, FP1: 5'-
actccaggcttgtcttggctcc-3', RP1: 5'-tgggagcagggctctcccaa-3',
FP2: 5'-ttgcctaggaactccaggcttgt-3', RP2: 5'-gcagcggcacttctct-
gatgag-3', FP3: 5'-tgctgctcttgctgccccgt-3', RP3: 5'-aaagaatg-
tagcaaaccggtcaggg-3'), MT1E (GenBank Accession No.:
NM_175617, FP: 5'-ccttcttccccaggctgctgt-3', RP: 5'-aat-
gcagcaaatggctcagtgttg-3'), MT1G (GenBank Accession No.:
BC035287, FP: 5'-gcatctgcaaaggggcatcg-3', RP: 5'-aaag-
gaatgtagcaaaggggtcaaga-3'), MT1L (GenBank Accession
No.: BC070351, FP: 5'-gggctcctgctcctgtgcca-3', RP: 5'-
ggaatgtagcaaatgctcagggttg-3'), MT1M (GenBank Accession
No.: NM_176870, FP: 5'-tggtgtctcctgcgcctgca-3', RP: 5'-aat-
gcagcaaatggctcagtatcgtatt-3'), MT1X (GenBank Accession
No.: BC053882, FP: 5'-tgctgctcctgctgccctgt-3', RP: 5'-aaaa-
gatgtagcaaacgggtcaggg-3'), MT2A (GenBank Accession
No.: NM_005953, FP: 5'-cgactctagccgcctcttca-3', RP: 5'-
gaaaaaggaatatagcaaacggtcac-3'), RPL19 (GenBank Acces-
sion No.: NM_000981, FP: 5'-ggctgctcagaagataccgtg-3',
RP: 5'-ggcgcttgcgtgcttccttg-3') and B2M (GenBank Acces-
sion No.: NM_004048, FP: 5'-agcgtactccaaagattcaggtt-3',
RP: 5'-tacatgtctcgatcccacttaactat-3'). Specificity of PCR
products obtained was characterized by melting-curve
analysis followed by gel electrophoresis and DNA
sequencing.
The following primers were used to amplify fragments for
in-situ hybridization: ATP1A3 (GenBank Accession No.:
NM_152296; FP: 5'-tcaagaaggaggtggctatg-3', RP: 5'-
gagaagcagccagtgatgat-3');NRGN (GenBank Accession No.:
NM_006176; FP: 5'-gactaggccagaactgagca-3', RP: 5'-agt-
ggcacggagatgtagg-3'); PVALB (GenBank Accession No.:
NM_002854; FP: 5'-agttgcaggatgtcgatgac-3', RP: 5'-cca-
gagtggagaattcgtca-3'); ANXA2 (GenBank Accession No.:
NM_004039; FP: 5'-gatcatctgctccagaacca-3', RP: 5'-gagtcat-
acagccgatcagc-3').
Comparison with SALS spinal-cord and AD hippocampus 
expression data
For SALS spinal-cord data, series GSE833 [4] of GEO was
imported into Excel (Microsoft Corp.), and all UniGene
ID numbers were updated (January 2006) using probe
identities of the HuGeneFL array (Affymetrix, Inc.) in the
NetAffx™ Analysis Center (Affymetrix, Inc.). Fold-changes
were calculated for five SALS samples (GSM6827,
GSM6828, GSM6834, GSM6835, GSM6836) vs. four con-
trol samples (GSM6826, GSM6829, GSM6830,
GSM6831), for genes with a corresponding UniGene ID
and showing a signal level of > 100 in at least five of these
nine samples (3276 genes of a total of 7070 present on the
HuGeneFL array). For 2266 of these genes the equivalent,
quality-filtered (see above) non-redundant Agilent probes
with the lowest uncorrected P value (see GenMAPP analy-
sis above) were short-listed to calculate a correlation coef-
ficient r for the expression ratios in spinal cord and motor
cortex using Excel. A correlation coefficient was deter-
mined for all 2266 shared genes and for 23 shared genes
corresponding to candidate genes identified in motor cor-
tex by gene-based analysis, respectively.
For AD hippocampus data, an analogous procedure was
followed, using seven severe-AD samples (GSM21203,
GSM21206, GSM21207, GSM21208, GSM21212,
GSM21213, GSM21229) vs. nine controls (GSM21215,
GSM21217, GSM21218, GSM21219, GSM21220,
GSM21221, GSM21226, GSM21231, GSM21232) of the
GEO series GSE1297, and including genes showing a sig-
nal level of > 100 in at least eight of these 16 samples,
resulting in a shared dataset of 6375 reliably detectable
genes. A correlation coefficient was determined for the
expression ratios diseased vs. control for these shared
genes and for 38 shared genes identified as differentially
expressed in our SALS study, respectively.
Immunofluorescence
Tissue slices were submerged for 10 minutes in acetone at
-20°C, followed by washes in phosphate-buffered saline
(PBS), and incubation with 0.5% Triton in blocking solu-
tion (2% fetal calf serum, 2% bovine serum albumin,
0.2% fish-skin gelatine) for 10 minutes. Tissue slices were
then incubated with 10-mM copper (II) sulfate and 50-
mM ammonium acetate (pH 5.0) for 30 min to quench
autofluorescence, followed by washes with PBS. Primary
antibodies were co-incubated over-night at 4°C at dilu-
tions of 1:50 for AQP1 (AQP1 antibody H-55, Santa Cruz
Biotechnology, Inc.) and 1:3000 for neurofilaments (200Page 21 of 26
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blocking solution without Triton X-100, followed by
washes in PBS and co-incubation of secondary antibodies
at room temperature at dilutions of 1:1500 anti-mouse
Alexa Fluor 568 (A-11034, Molecular Probes) and 1:500
anti-rabbit Alexa Fluor 488 (A-21124, Molecular Probes).
Tissue sections were then washed in PBS, incubated with
Hoechst33342 as a DNA counter stain, washed in PBS,
briefly air-dried, and mounted for microscopy in 10%
Mowiol, 1% 1,4-Diazabicyclo [2.2.2]octane, and 25%
glycerol in 0.1-M Tris buffer (pH 8). Images were acquired
using an Axiovert 200 M microscope with the AxioVision
4.5 image acquisition software, the Apotome module and
the transparency projection option for Z stacks of the
Inside4D visualization module (all Carl Zeiss Inc.).
Abbreviations
For Unigene cluster IDs of candidate genes see Figure 3,
conforming to the HUGO Gene Nomenclature Commit-
tee (HGNC) database (see [135]). All abbreviations are
defined at their first appearance in the text, and in the leg-
ends of tables and figures, as follows:
AD – Alzheimer's disease
ALS – amyotrophic lateral sclerosis
BP – biological process
CC – cellular component
EGL – external granular layer
EPL – external pyramidal layer
FALS – familial ALS
FP – forward primer
GO – gene ontology
IGL – internal granular layer
IPL – internal pyramidal layer
LMN – lower motoneuron
NF – neurofilament
MF – molecular function
MFL – multiform layer
ML – molecular layer
RP – reverse primer
qRT-PCR – quantitative reverse-transcriptase PCR
SALS – sporadic ALS
TCA – tricarboxylic acid cycle
UMN – upper motoneuron
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